에 대한 최신 뉴스 Brenmiller Energy (NASDAQ:BNRG) 주식

Brenmiller Energy

Brenmiller Energy Ltd is an Israel-based company. It is a technology company that develops, produces, markets, and sells thermal energy storage. The technology of the company allows electrification and decarbonization of the industrial industry sector for integration with renewable energy sources and further reduction of carbon emissions.

Earnings

News

After-Hours Center

Movers

BNRG

브렌밀러 에너지(NASDAQ:BNRG)의 주식은 회사가 목요일 시장 마감 후 상반기 재무 결과를 발표한 후 130% 이상 급등했다. 자세한 내용은 다음과 같다.

목요일 실적 발표 후 130% 이상 폭등한 브렌밀러 에너지의 주식에 무슨 일이?

Brenmiller Energy Ltd

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

BJDX

SMST

LIFW

SMCX

LIFWW

Numinus Wellness Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/NUMIF#OTCQX">NUMIF</a>), a leader in <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-assisted mental health care</a>, has <a href="https://www.investors.numinus.com/news/news-details/2024/Numinus-Wellness-Announces-Sale-of-Clinics-and-Unique-Data-Partnership-to-Increase-Access-to-Mental-Health-Care/default.aspx">announced</a> a definitive agreement with Stella, an interventional psychiatry practice, to sell its five wellness clinics in Utah for a total of $3.53 million. The transaction, expected to close by November 30, marks a strategic shift for Numinus, as it pivots towards <a href="https://www.benzinga.com/markets/cannabis/24/09/40845569/mdma-therapy-for-ptsd-faces-fda-delay-are-there-other-ways-forward">developing technology-driven solutions</a> aimed at enhancing the efficiency of mental health care providers.
<h3 class="wp-block-heading">Tech Partnership To Redefine Mental Health Clinics</h3>
In addition to the sale, Numinus and Stella will collaborate on a data-sharing initiative to launch an innovative clinic management platform. By leveraging operational insights from Stella's 12 clinics, Numinus plans to develop a software solution designed to streamline clinic operations, enhance patient outcomes and support insurance reimbursement processes.
"This transaction marks an exciting new chapter in Numinus' strategy to reshape behavioral health care," said Payton Nyquvest, founder and CEO of Numinus. "Leveraging our expertise in patient care, we're now accelerating our mission by focusing on cutting-edge technology solutions. Through our partnership with Stella, we gain unprecedented access to operational data that will enable us to develop a SaaS (software as a service) solution to redefine how clinics operate."
<h3 class="wp-block-heading">Stella Takes Over Utah Operations</h3>
Stella, known for its focus on treating PTSD, anxiety and depression through biological modalities, will assume control of Numinus' Utah clinics. The acquisition includes an upfront payment of $2.08 million, followed by $750,000 in installments throughout 2025, and up to $700,000 in deferred compensation.
"Stella's expansion into Utah brings additional life-changing treatments to the community while supporting Numinus' broader tech initiatives," stated Michael Gershenzon, co-founder and CEO of Stella. "This partnership reflects our commitment to improving behavioral health systems and processes, ultimately enhancing patient care."
<h3 class="wp-block-heading">An Asset-Light Business Model With Enhanced Focus</h3>
With the sale of its clinics, Numinus will shift towards an asset-light model, focusing on its business units like Cedar Clinical Research and the Numinus Network. The strategy aims to integrate clinical research, practitioner training and technology solutions, supporting mental health providers worldwide. The move is part of a broader effort to ease the operational burdens faced by healthcare professionals, particularly as demand for treatments like <a href="https://www.benzinga.com/topic/ketamine-therapy">ketamine</a> and Spravato continues to rise.
"Stella will bolster our clinical solutions offering, leveraging their deep expertise in patient care," Nyquvest added. "We expect strong demand for our Numinus Network Solutions as mental health practitioners navigate growing requests for care."
Cover image made with AI

Cannabis

Psychedelics

NUMIF

Numinus Wellness Sells US Clinics, Partners With Stella For Tech-Driven Mental Health Solutions

President-elect Donald Trump has chosen former Representative Doug Collins (R-GA) to lead the <a href="https://www.benzinga.com/cannabis">U.S. Department of Veterans Affairs (VA). </a>
The decision has sparked discussions about how the agency might handle medical cannabis issues, given his inconsistent track record on the issue, as <a href="https://www.marijuanamoment.net/trumps-pick-to-lead-va-voted-against-letting-agency-doctors-recommend-medical-marijuana-to-veterans-before-he-adopted-a-pro-reform-position/">reported</a> Marijuana Moment.
<h3 class="wp-block-heading">Collins' Record On Cannabis</h3>
During his time in Congress, Collins opposed efforts to expand access to medical cannabis for veterans. Between 2014 and 2016, he voted against three proposals that would have allowed VA doctors to recommend cannabis to their patients.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/42018478/trumps-cabinet-choices-will-his-administration-support-or-restrict-cannabis">Trump&#8217;s Cabinet Choices: Will His Administration Support Or Restrict Cannabis?</a>
Collins' views began to shift in 2019. He supported the STATES Act, which would protect state marijuana programs from federal interference, and co-signed a letter with Rep. Matt Gaetz (R-FL), urging Congress to take action on cannabis policy. 
"We believe this Committee and this Congress must act to clarify the rights and responsibilities, relative to cannabis, of individuals, physicians, businesses, medical patients, and law enforcement officials," they wrote.
Later that year, Collins backed a bipartisan bill to protect banks that serve marijuana businesses in states where it is legal. However, he did not take part in a 2020 vote on federal cannabis legalization.
<h3 class="wp-block-heading">Collins' Stance On Psychedelics</h3>
When it comes to psychedelics, there isn't much known about Collins's stance. However, his shifting views on cannabis policy hint that he could be open to exploring different approaches.
<h3 class="wp-block-heading">Cannabis At The VA</h3>
VA policy has long prohibited its doctors from recommending cannabis, citing marijuana's classification as a Schedule I controlled substance under federal law. This stance has remained consistent across both Republican and Democratic administrations, despite growing support for change in Congress.
Recent efforts to address this issue include a Senate Appropriations Committee request for the VA to explore cannabis as an alternative to opioids. Lawmakers have also introduced measures that would allow VA doctors to recommend cannabis in states where it is legal. These efforts have gained bipartisan support, but none have yet become law.
Veterans service organizations have pushed for further reforms, including expanded research into the potential benefits of cannabis. Last year, a Senate committee approved a bill to study cannabis for veterans with certain medical conditions, but it failed to advance to a floor vote.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/42017583/trumps-go-wild-on-health-plan-puts-rfk-jr-in-charge-what-it-means-for-cannabis-and-psychedelics-reform">Trump&#8217;s &#8216;Go Wild On Health&#8217; Plan Puts RFK Jr. In Charge: What It Means For Cannabis And Psychedelics Reform</a></li>
</ul>
Cover image made with AI.

Government

Politics

Markets

Trump-Appointed Doug Collins To Lead VA: What's Next For Cannabis and Psychedelics In Veterans' Healthcare?

Chardan Capital analyst Daniil Gataulin maintains Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) with a Buy and maintains $6 price target.

Price Target

Analyst Ratings

CLSD

Chardan Capital Maintains Buy on Clearside Biomedical, Maintains $6 Price Target

Chardan Capital analyst Daniil Gataulin maintains Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) with a Buy and maintains $11 price target.

CGTX

Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target

Telsey Advisory Group analyst Cristina Fernandez maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Outperform and maintains $165 price target.

Telsey Advisory Group Maintains Outperform on Williams-Sonoma, Maintains $165 Price Target

– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation –
– Syndax to host conference call today at 6:00 p.m. ET –
WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj&#xAE; (revumenib) as the first and only menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older. The FDA previously granted Breakthrough Therapy and Fast Track designations as well as Priority Review for Revuforj. The New Drug Application (NDA) received approval through the FDA's Real Time Oncology Review (RTOR) program.

Biotech

General

SNDX

Syndax Announces FDA Approval Of Revuforj, The First And Only Menin Inhibitor To Treat Adult And Pediatric Patients With Relapsed Or Refractory Acute Leukemia With A KMT2A Translocation

IT Tech Packaging (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ITP#AMEX">ITP</a>) reported quarterly losses of $(0.20) per share. This is unchanged from the same period last year. The company reported $25.08 million in sales this quarter. This is a 59.03 percent increase over sales of $15.77 million the same period last year.

IT Tech Packaging Q3 EPS $(0.20), Same YoY, Sales $25.08M Up From $15.77M YoY

RumbleOn, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBL#NASDAQ">RMBL</a>) (the "Company" or "RumbleOn") announced today that the close of business (4:00 p.m. Central Time) on November 25, 2024 has been fixed as the record date (the "Record Date") for its previously announced proposed $10.0 million registered equity rights offering (the "Rights Offering"), which was announced in a Form 8-K filed with the U.S. Securities and Exchange Commission ("SEC") on November 12, 2024.

Offerings

RMBL

RumbleOn Announces That The Close Of Business On November 25, 2024 Has Been Fixed As The Record Date For Its Previously Announced Proposed $10M Registered Equity Rights Offering

Telsey Advisory Group analyst Dana Telsey maintains European Wax Center (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) with a Outperform and maintains $8 price target.

EWCZ

Telsey Advisory Group Maintains Outperform on European Wax Center, Maintains $8 Price Target

<a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf" title="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf</a>

FOUR

Shift4 Payments Will Replace R1 RCM In The S&P Midcap 400 Effective Prior To The Opening Of Trading On Wednesday, November 20

China Green Agriculture, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CGA#NYSE">CGA</a>) has changed its name to Enlightify Inc., effective November 25, 2024. Its ticker symbol will change to ENFY effective November 25, 2024, and it is expected to begin trading under that symbol on November 26, 2024. The Company mainly produces and distributes humic acid-based compound fertilizers, other varieties of compound fertilizers and agricultural products through its subsidiaries in China.

China Green Agriculture Changes Name to Enlightify Inc.; Its Ticker Symbol Will Change To 'ENFY' Effective November 25, 2024, And It Is Expected To Begin Trading Under That Symbol On November 26, 2024

Alpha Cognition (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>) reported quarterly losses of $(0.31) per share. This is a 63.1 percent increase over losses of $(0.84) per share from the same period last year.

ACOG

Alpha Cognition Q2 EPS $(0.31) Up From $(0.84) YoY

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) with a Buy and maintains $31 price target.

NRXP

D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $31 Price Target

D. Boral Capital analyst Jason Kolbert maintains VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) with a Buy and maintains $5 price target.

VNRX

D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target

RNW, BNRG, and AGR are among utility movers

SUUN, WAVE, BNRG, and OKLO are among utility movers

SUUN and BNRG are among utility movers

OKLO, FLNC, BNRG, and WAVE are among utility movers

Brenmiller Energy receives minimum bid price notification from Nasdaq

Brenmiller Energy GAAP EPS of -$0.45

Brenmiller Energy Ltd., Agape ATP, and Focus Universal are the 3 Penny Stocks to watch on September 3, 2024, based on&nbsp;TipRanks' Penny Stock Sc...

3 Penny Stocks to Watch Now, 9/03/24

Brenmiller Energy, Mullen Automotive, and MicroCloud Hologram are the 3 Penny Stocks to watch on September 5, 2024, based on TipRanks' Penny Stock ...

3 Penny Stocks to Watch Now, 9/05/24

Brenmiller Energy raises $2M from at-the-market equity offering at $2.19 per share

Brenmiller Energy establishes JV in Europe with Green Enesys and Viridi RE

ATPC

CREG

FCUV

FLNC

HOLO

MULN

OKLO

SUUN

WAVE

Press Releases

Brenmiller Energy Establishes Joint Venture in Europe to Scale bGen™ Technology Adoption Across Europe

Exclusive: Brenmiller Energy COO On-Demand Interview Wednesday October 23, 2024

Brenmiller Energy Scores "TIME Magazine 'Best Inventions of 2023'" and Bloomberg BNEF 2024 Pioneers Finalist Accolades…Here's Why

Brenmiller Energy to Engage with Entelios to Deploy Sustainable Energy Practices that Optimize Revenue Streams for bGen™ Users in Germany, a Market Estimated to Reach $2.9 Billion by 2028

Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now

Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now

Brenmiller Issues 2023-2024 ESG Report: Charting the Course to Net-Zero

Brenmiller Energy's Planned Partnership With Entelios Could Ultimately Power Over 750,000 Homes ($BNRG)

Brenmiller Energy Targets Multi-Decade High Demand for Thermal Energy Storage and Net-Zero Solutions

Brenmiller Energy's Game-Changing Thermal Energy Storage Technology Is Changing The Way Industrial Energy Is Sourced and Managed

AEMD

ASPI

BIXT

BTVRF

BVAXF

CSE:BIOV

CSE:ELEM

CSE:PLUG

CYIO

ELMGF

EUDA

GIFT

GOSS

ICON

IMRN

LDTC

MNMRF

NCSM

NRXBF

PGEZF

PLGGF

RGBP

SEVCF

SIGY

STXPF

TSX:VOXR

TSXV:BTV

TSXV:MNRG

TSXV:NRX

TSXV:PGE

TSXV:STU

TSXV:XBOT

VANI

VIOT

VOXR

XBOTF

브렌밀러 에너지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNRG#NASDAQ">BNRG</a>)의 주식은 회사가 목요일 시장 마감 후 상반기 재무 결과를 발표한 후 130% 이상 급등했다. <a href="https://www.benzinga.com/pressreleases/24/08/b40638143/brenmiller-reports-first-half-2024-financial-results-upcoming-catalysts-include-potential-mileston" target="_blank" rel="noopener" data-google-interstitial="false">자세한 내용</a>은 다음과 같다.
상세 내용: 브렌밀러 에너지는 상반기 주당 손실을 45센트로 보고했는데, 이는 전년 동기 대비 주당 3.02달러의 손실에서 긍정적으로 큰 폭 증가한 것이다. 이 회사는 인공 지능(AI) 데이터센터에 냉열에너지 저장장치(CTES)를 제공하기 위한 역량을 확장하는 방법을 모색하고 있다고 발표했다.
브렌밀러는 최대 5억 달러 가치의 프로젝트 파이프라인을 구축했다고 밝혔다.
다음 읽기: <a href="https://www.benzinga.com/news/24/08/40633593/whats-going-on-with-sofi-technologies-stock">소파이 테크놀로지스 주식에 무슨 일이 일어나고 있나요?</a>
"AI 컴퓨팅의 급속한 성장과 AI 애플리케이션을 둘러싼 자금이 풍부한 생태계는 CTES를 사용하여 충족할 수 있다고 믿는 다운스트림 탈탄소화 및 재정적 기회를 창출했다. 우리의 bGen&#x2122; 열 배터리를 데이터 센터 애플리케이션에 적용하려면 최소한의 투자가 필요할 것으로 예상된다"고 브렌밀러의 CEO인 아비 브렌밀러(Avi Brenmiller)가 말했다.
"우리의 선구적인 bGen&#x2122; 열 배터리는 지속 가능한 열에 대한 온디맨드 액세스에 대한 증가하고 대부분 충족되지 않은 요구를 지속적으로 지원한다. 우리는 잠재적으로 5억 달러의 가치를 지닌 인상적인 프로젝트 파이프라인을 구축했으며, 고객들에게 의미 있는 비용 절감과 배출 감소를 제공하고, 회사에 반복적인 수익과 주주 가치를 창출하기 위해 팀이 하루도 빠짐없이 열심히 이 파이프라인을 추진하고 있다.&#8221;
<a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" target="_blank" rel="noopener">Benzinga Pro</a>에 따르면, 브렌밀러 에너지의 주식은 이번 거래에서 평소 일일 거래량의 10배 이상의 거래량을 기록하며 급등하고 있다.
BNRG 주가 움직: <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>에 따르면, 브렌밀러 에너지의 주식은 목요일 애프터 마켓에서 135.66% 상승한 1.52달러로 거래되었다.
이미지 출처: Moondance from Pixabay
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Brenmiller Energy

뉴스

에 대한 최신 뉴스 Brenmiller Energy (NASDAQ:BNRG) 주식

목요일, 8월 29, 2024

뉴스

파트너 / 기고자

벤징가 글로벌